Completed PHASE3 INTERVENTIONAL 2-arm NCT00801944

Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms (SUNRISE)

Solifenacin in the Treatment of Urgency Symptoms of Overactive Bladder in a Rising Dose, Randomized, Placebo-controlled, Double-blind Trial

Sponsor: Astellas Pharma Inc

Conditions Urinary Bladder, Overactive

Interventions Placebo Solifenacin succinate

Updated 7 times since 2017 Last updated: Sep 17, 2014 Started: Apr 30, 2004 Primary completion: Oct 31, 2005 Completion: Oct 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00801944, this PHASE3 trial focuses on Urinary Bladder, Overactive and remains completed. Sponsored by Astellas Pharma Inc, it has been updated 7 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Inc

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abrantes, Portugal , Aichach, Germany , Al Mansurah, Egypt , Antwerp, Belgium , Athens, Greece , Bad Neuenaher, Germany , Bamberg, Germany , Banska Bysterica, Slovakia , Barcelona, Spain , Bari, Italy and 68 more locations